Q-omics provides the consensus-scored ZFP2 profile across patient tissues and cancer cell-line models. ZFP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFP2 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, ZFP2 RNA expression shows 19,967 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ZFP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP2 survival associations across molecular data types. ZFP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP2 RNA expression–survival associations across cancer types. High ZFP2 expression shows favorable associations in KIRC, HNSC, ACC, MESO, PAAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFP2 RNA expression.
This table summarizes ZFP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZFP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP2 shows lower tumor expression in KICH, COAD, THCA, HNSC, BLCA and LUSC. The KICH box plot shows higher ZFP2 RNA expression in normal versus tumor tissue (log2 FC = −1.533, t-test p < 0.001).
This table shows molecular features associated with ZFP2 in patient tissues and cancer cell lines. In patient samples, ZFP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
